FI900332A0 - Expressionssystem foer produktion av chimaera monoklonala antikroppar. - Google Patents

Expressionssystem foer produktion av chimaera monoklonala antikroppar.

Info

Publication number
FI900332A0
FI900332A0 FI900332A FI900332A FI900332A0 FI 900332 A0 FI900332 A0 FI 900332A0 FI 900332 A FI900332 A FI 900332A FI 900332 A FI900332 A FI 900332A FI 900332 A0 FI900332 A0 FI 900332A0
Authority
FI
Finland
Prior art keywords
monoclonala
expressionssystem
antikroppar
chimaera
monoclonal antibodies
Prior art date
Application number
FI900332A
Other languages
English (en)
Finnish (fi)
Inventor
Bradley R Zerler
Original Assignee
Molecular Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Therapeutics Inc filed Critical Molecular Therapeutics Inc
Publication of FI900332A0 publication Critical patent/FI900332A0/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FI900332A 1989-01-24 1990-01-22 Expressionssystem foer produktion av chimaera monoklonala antikroppar. FI900332A0 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30121689A 1989-01-24 1989-01-24
US44170289A 1989-12-04 1989-12-04

Publications (1)

Publication Number Publication Date
FI900332A0 true FI900332A0 (fi) 1990-01-22

Family

ID=26972226

Family Applications (1)

Application Number Title Priority Date Filing Date
FI900332A FI900332A0 (fi) 1989-01-24 1990-01-22 Expressionssystem foer produktion av chimaera monoklonala antikroppar.

Country Status (12)

Country Link
EP (1) EP0380068B1 (ja)
JP (1) JPH02295487A (ja)
AT (1) ATE81153T1 (ja)
AU (1) AU641907B2 (ja)
CA (1) CA2008259A1 (ja)
DE (1) DE69000338T2 (ja)
DK (1) DK0380068T3 (ja)
ES (1) ES2052077T3 (ja)
FI (1) FI900332A0 (ja)
IL (1) IL93118A0 (ja)
NZ (1) NZ232201A (ja)
PT (1) PT92900A (ja)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2141076T3 (es) 1988-09-01 2000-03-16 Bayer Ag Proteina del receptor de rinovirus humano que inhibe la infectividad del virus.
US6051231A (en) * 1988-09-01 2000-04-18 Bayer Corporation Antiviral methods and prepations
ZA896668B (en) * 1988-09-01 1990-06-27 Molecular Therapeutics Inc A human rhinovirus receptor protein that inhibits virus infectivity
US6143298A (en) * 1988-09-01 2000-11-07 Bayer Corporation Soluble truncated forms of ICAM-1
US6514936B1 (en) 1988-09-01 2003-02-04 Bayer Corporation Antiviral methods using human rhinovirus receptor (ICAM-1)
US5686582A (en) * 1990-07-20 1997-11-11 Bayer Corporation Multimeric forms of human rhinovirus receptor protein
US6107461A (en) * 1990-07-20 2000-08-22 Bayer Corporation Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use
EP0468257B1 (en) * 1990-07-20 1999-09-01 Bayer Corporation Multimeric form of human rhinovirus receptor protein
US5686581A (en) * 1990-07-20 1997-11-11 Bayer Corporation Multimeric form of human rhinovirus receptor protein
GB2279077B (en) * 1990-12-21 1995-06-14 Celltech Ltd Therapeutic compositions comprising recombinant antibodies specific for the TNFalpha
US5698195A (en) * 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
EP1681305A3 (en) * 1991-03-18 2008-02-27 New York University Monoclonal and chimeric antibodies specific for human tumor necrosis factor
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
AU689489B2 (en) * 1993-07-30 1998-04-02 Oravax, Inc Monoclonal IgA antibody against respiratory syncytial virus
KR20010023179A (ko) * 1997-08-22 2001-03-26 유니버시티 오브 겔프 알에서의 단백질 생산방법
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
TWI327597B (en) 2001-08-01 2010-07-21 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
US8415291B2 (en) 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
FR3004184B1 (fr) 2013-02-26 2016-03-18 Agronomique Inst Nat Rech Anticorps anti-gluten desamide et utilisations.
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
KR20190113858A (ko) 2017-01-30 2019-10-08 얀센 바이오테크 인코포레이티드 활성 건선성 관절염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
MX2019009377A (es) 2017-02-07 2019-12-11 Janssen Biotech Inc Anticuerpos anti-tnf, composiciones y metodos para el tratamiento de la espondilitis anquilosante activa.
AU2020279987A1 (en) 2019-05-23 2021-11-18 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2188941B (en) * 1986-04-14 1990-06-06 Bayer Ag Monoclonal antibodies recognizing human interleukin-2-receptor
CA1340456C (en) * 1986-07-07 1999-03-23 Hubert J.P. Schoemaker Chimeric rodent/human immunoglobulins specific for tumor-associated antigens
KR900700134A (ko) * 1988-04-15 1990-08-11 원본미기재 Il-2 수용체-특이적 키메릭 항체
WO1989009825A1 (en) * 1988-04-16 1989-10-19 Celltech Limited Method for producing recombinant dna proteins

Also Published As

Publication number Publication date
DK0380068T3 (da) 1992-11-02
AU4876690A (en) 1990-08-02
EP0380068A1 (en) 1990-08-01
EP0380068B1 (en) 1992-09-30
ES2052077T3 (es) 1994-07-01
ATE81153T1 (de) 1992-10-15
DE69000338D1 (de) 1992-11-05
CA2008259A1 (en) 1990-07-24
NZ232201A (en) 1992-04-28
PT92900A (pt) 1990-07-31
AU641907B2 (en) 1993-10-07
DE69000338T2 (de) 1993-02-25
IL93118A0 (en) 1990-11-05
JPH02295487A (ja) 1990-12-06

Similar Documents

Publication Publication Date Title
FI900332A0 (fi) Expressionssystem foer produktion av chimaera monoklonala antikroppar.
ATE143052T1 (de) Chimärisches murine-mensch-immunoglobulin, spezifisch für tumorassoziertes 17-1a antigen
AU1042192A (en) Recombinant antibodies specific for a growth factor receptor
AU2097692A (en) Method for the production of monoclonal antibodies utilizing a germfree animal
TW222279B (ja)
FI101937B1 (fi) Menetelmä monoklonaalisen vasta-aineen tuottamiseksi, joka reagoi ihmisen cachectiinin kanssa
PL313260A1 (en) Monoclonal antibodies having properties making them able to cause apoptosis
DE59209129D1 (de) Verwendung von Antikörper enthaltenden Präparationen zur Immunsuppression
EP0257778A3 (en) Apolipoprotein b-specific monoclonal antibodies produced by two novel hybridomas
DE3581288D1 (de) Antileishmania monoklonale antikoerper, diese antikoerper ausscheidende hybridomas, von diesen antikoerpern erkannte leishmaniaantigene, verfahren zur herstellung und verwendung von diesen monoklonalen antikoerpern und antigenen.
DE3582358D1 (de) Monoklonaler antikoerper und verfahren zur quantitativen bestimmung von immunoglobulinen mittels dieses antikoerpers.
MX9207459A (es) Anticuerpos humanizados reactivos con gpiib/iiia.
SE9201281L (sv) Nya humana monoklonala antikroppar och förfarande för framställning därav
DE59309133D1 (de) Granulozytenbindende Antikörperkonstrukte, ihre Herstellung und Verwendung
EP0287397A3 (en) Monoclonal antibody specific to human pancreatic phospholipase a2
NO962125L (no) Anti-idiotypiske antistoffer som induserer en immunrespons mot epidermal vekstfaktorreseptor
AU625398B2 (en) Monoclonal antibody recognizing gamma atrial natriuretic polypeptide
DE3579808D1 (de) Anti-urokinase monoklonaler antikoerper, seine herstellung und verwendung.
DE3881101D1 (de) Monoklonal-antikoerper und methode fuer die bereitung von hybridoma, produzierend diese antikoerper.
EP0332421A3 (en) Monoclonal antibodies recognizing human psti, hybridomas producing the same, and their preparation and use

Legal Events

Date Code Title Description
FA Application withdrawn

Owner name: MOLECULAR THERAPEUTICS INC.